Increase in venous complications associated with etomidate use during a propofol shortage: An example of clinically important adverse effects related to drug substitution

Ochsner Journal

Volumn 11, Issue 2, 2011, Pages 143-146

  Kosarek, Logan ^a   Hart, Stuart R ^a   Schultz, Lucy ^a   Digiovanni, Neil ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Etomidate; Phlebitis; Propofol shortage; Thrombophlebitis

Indexed keywords

ESMOLOL; ETOMIDATE;

ADULT; ANESTHESIA COMPLICATION; ANESTHESIA INDUCTION; ARTICLE; CLINICAL ARTICLE; DRUG USE; FEMALE; HUMAN; INJECTION SITE PAIN; MALE; PHLEBITIS; THROMBOPHLEBITIS; VEIN DISEASE;

EID: 79958822062     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Doenicke A. Clinical experimental studies and first report on clinical experience with a new IV hypnotic. Proceedings of the 6th International Refresher Course on Clinical Anesthesiology. Vienna, May 21-25, 1973:22-25.
2. Doenicke AW, Roizen MF, Kugler J, Kroll H, Foss J, Ostwald P. Reducing myoclonus after etomidate. Anesthesiology. 1999;90(1):113-119.
3. Holdcroft A, Morgan M, Whitwam JG, Lumley J. Effect of dose and premedication on induction complications with etomidate. Br J Anaesth. 1976;48(3):199-205.
4. Doenicke A, Roizen MF, Nebauer AE, Kugler A, Hoernecke R, Beger-Hintzen H. A comparison of two formulations for etomidate, 2-hydroxypropyl-beta-cyclodextrin (HPCD) and propylene glycol. Anesth Analg. 1994;79(5):933-939.
5. Doenicke AW, Roizen MF, Hoernecke R, Lorenz W, Ostwald P. Solvent for etomidate may cause pain and adverse effects. Br J Anaesth. 1999;83(3):464-466.
6. Zacharias M, Clarke RS, Dundee JW, Johnston SB. Venous sequelae following etomidate. Br J Anaesth. 1979;51(8):779-783.
7. Bedichek E, Kirschbaum B. A case of propylene glycol toxic reaction associated with etomidate infusion. Arch Intern Med. 1991;151(11):2297-2298.
8. Demey HE, Daelemans RA, Verpooten GA, et al. Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med. 1988;14(3):221-226.
9. Decousus H, Epinat M, Guillot K, Quenet S, Boissier C, Tardy B. Superficial vein thrombosis: risk factors, diagnosis, and treatment. Curr Opin Pulm Med. 2003;9(5):393-397.
10. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119(1 Suppl): 176S-193S.
11. Doenicke A, Kugler A, Vollmann N, Suttmann H, Taeger K. [Etomidate using a new solubilizer. Experimental clinical studies on venous tolerance and bioavailability]. Anaesthesist. 1990;39(10):475-480. German.
12. Nyman Y, Von Hofsten K, Palm C, Eksborg S, Lönnqvist PA. Etomidate-Lipuro is associated with considerably less injection pain in children compared with propofol with added lidocaine. Br J Anaesth. 2006;97(4):536-539.
13. Rühmann I, Maier C. [The modification of injection pain and the incidence of thrombophlebitis following etomidate]. Anasth Intensivther Notfallmed. 1990;25(Suppl 1):31-33. German.
14. Yavascaoglu B, Kaya FN, Ozcan B. Esmolol pretreatment reduces the frequency and severity of pain on injection of rocuronium. J Clin Anesth. 2007;19(6):413-417.
15. Ganta R, Verma R. Pain on injection and venous sequelae following two formulations of etomidate. Eur J Anaesthesiol. 1989;6(6):431-434.